French pharma makes move into haemophilia market.
Dr Fiona Marshall joins MSD from Sosei from Heptares, the UK biotech company she co-founded more than a decade ago, and which was acquired by Sosei in 2015.
Drug likely to cost just under £10,000 per six-monthly injection.
This week’s news
Approach could reduce use of cancer drugs.
Companies will develop and market several biosimilars
Companies will offer combination of digital and in-person healthcare.
Out of 4,000 studies, review found only 16 were high quality.
KEYNOTE-189 results could see US Merck tighten its grip in cancer immunotherapy.